Drug Profile
Intetumumab
Alternative Names: CNTO 095; CNTO-95Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Centocor
- Developer Janssen Biotech; Janssen-Cilag
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Prostate cancer
Most Recent Events
- 14 Oct 2011 Intetumumab licensed to BeiGene in Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan
- 19 Nov 2009 Preclinical pharmacodynamics data presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb